Akorn gets U.S. approval to buy Hi-Tech Pharmacal, with conditions
WASHINGTON, April 14
WASHINGTON, April 14 (Reuters) - Generic drugmaker Akorn Enterprises Inc has won U.S. antitrust approval to buy rival Hi-Tech Pharmacal Inc on condition that it sell three generic prescription eye medications and two generic topical anesthetics, the Federal Trade Commission said on Monday.
The deal, which is valued at $640 million, will allow Akorn to expand its eye drug portfolio to oral liquids and ointments.
- Islamic State threat 'beyond anything we've seen': Pentagon
- British Muslims blame jihadi subculture after beheading video |
- Israeli air strike kills three Hamas commanders in Gaza |
- U.S. aid workers who survived Ebola leave Atlanta hospital |
- National Guard to withdraw from riot-torn Ferguson, Missouri |